3-Fluorobenzyl bromide | CAS:456-41-7

We serve 3-Fluorobenzyl bromide CAS:456-41-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Fluorobenzyl bromide

Chemical Name:3-Fluorobenzyl bromide
CAS.NO:456-41-7
Synonyms:Benzene, 1-(bromomethyl)-3-fluoro-; 
1-(bromomethyl)-3-fluorobenzene;
Molecular Formula:C7H6BrF
Molecular Weight:189.02500
 
Physical and Chemical Properties:
Density:1.541;
Boiling point:88oC;
Flash point:143oF;
Index of Refraction:1.546;
 
Specification:
Appearance:Colorless to yellow clear liquid
Purity(GC):≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis



Contact us for information like 3-Fluorobenzyl bromide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(bromomethyl)-3-fluorobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Fluorobenzyl bromide Use and application,3-Fluorobenzyl bromide technical grade,usp/ep/jp grade.


Related News: Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.2,2,3,3,3-Pentafluoropropan-1-amine manufacturer Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.Diethoxymethylsilane supplier The news, however, was greeted with skepticism online in China, with many — including numerous medical experts — questioning whether the findings were supported by clinical evidence from treating coronavirus patients.4-(Phthalimido)-Cyclohexanone vendor The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.He told Sky News: “SARS and MERS are the two severe coronaviruses. There are four that are very mild that people can get very regularly.”